These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

318 related articles for article (PubMed ID: 4371255)

  • 1. Dopaminergic nervous transmission in Parkinson's disease.
    Rinne UK; Sonninen V; Riekkinen P; Laaksonen H
    Med Biol; 1974 Jun; 52(3):208-17. PubMed ID: 4371255
    [No Abstract]   [Full Text] [Related]  

  • 2. [Biochemical and clinical correlations in Parkinson's disease].
    Barbeau A
    Rev Neurol (Paris); 1972 Aug; 127(2):253-64. PubMed ID: 4603361
    [No Abstract]   [Full Text] [Related]  

  • 3. [Study of dopamine and noradrenaline in the brains of three patients with Parkinson's disease who died in the course of treatment with L-dopa].
    Buscaino GA; Sori A; Campanella G
    Rev Neurol (Paris); 1972 Aug; 127(2):301-2. PubMed ID: 4666634
    [No Abstract]   [Full Text] [Related]  

  • 4. The role of the adrenergic system in the action of L-DOPA on brain serotonin.
    Algeri S; Cerletti C
    Adv Biochem Psychopharmacol; 1974; 10():257-9. PubMed ID: 4846542
    [No Abstract]   [Full Text] [Related]  

  • 5. The probenecid test in Parkinson's disease.
    Lakke JP; Korf J; Hoorntje S; Schut T; van Praag HM
    Psychiatr Neurol Neurochir; 1973; 76(2):139-46. PubMed ID: 4700931
    [No Abstract]   [Full Text] [Related]  

  • 6. Parkinson's disease: from brain homogenate to treatment.
    Hornykiewicz O
    Fed Proc; 1973 Feb; 32(2):183-90. PubMed ID: 4143953
    [No Abstract]   [Full Text] [Related]  

  • 7. Parkinson's disease and amine metabolites in cerebrospinal fluid: implications for L-Dopa therapy.
    Korf J; van Praag HM; Schut D; Nienhuis RJ; Lakke JP
    Eur Neurol; 1974; 12(5-6):340-50. PubMed ID: 4448192
    [No Abstract]   [Full Text] [Related]  

  • 8. Dopaminergic agonist effects on Parkinsonian clinical features and brain monamine metabolism.
    Rinne UK; Sonninen V; Marttila R
    Adv Neurol; 1975; 9():383-92. PubMed ID: 1096575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of brain 5-hydroxytryptamine in the central action of L-DOPA.
    Maj J; Pawlowski L; Sarnek J
    Adv Biochem Psychopharmacol; 1974; 10():253-6. PubMed ID: 4846541
    [No Abstract]   [Full Text] [Related]  

  • 10. Brain dopamine and noradrenaline in 3 Parkinsonians deceased during L-dopa treatment.
    Buscaino GA; Jori A; Campanella G
    Acta Neurol (Napoli); 1972; 27(6):537-44. PubMed ID: 4651485
    [No Abstract]   [Full Text] [Related]  

  • 11. Metabolic interactions of pyridoxine, levodopa, and carbidopa in Parkinson's disease.
    Mars H
    Trans Am Neurol Assoc; 1973; 98():241-5. PubMed ID: 4784941
    [No Abstract]   [Full Text] [Related]  

  • 12. [Central metabolism of dopamine and serotonin. III. Preliminary findings on the relations between dopamine metabolism and purine metabolism in the nervous system].
    Campanella G; Orefice G; Carrieri P; Mandarini A; Buscaino GA
    Acta Neurol (Napoli); 1976; 31(5):571-9. PubMed ID: 138341
    [No Abstract]   [Full Text] [Related]  

  • 13. Amantadine enhances dopamine and serotonin turnover in the MPTP model of Parkinson's disease.
    Altagracia M; Rojas P; Kravzov J; Rios C
    Proc West Pharmacol Soc; 1993; 36():289-91. PubMed ID: 7690973
    [No Abstract]   [Full Text] [Related]  

  • 14. [Biochemical bases of Parkinson disease].
    Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
    Recenti Prog Med; 1984 Oct; 75(10):889-901. PubMed ID: 6151219
    [No Abstract]   [Full Text] [Related]  

  • 15. Homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5HIAA) during L-dopa therapy of Parkinson's disease.
    van Woert MH; Bowers MB
    Neurology; 1970 Apr; 20(4):377. PubMed ID: 5534981
    [No Abstract]   [Full Text] [Related]  

  • 16. Metabolism of L-dihydroxyphenylalanine by patients with Parkinson's disease.
    Tyce GM; Muenter MD; Owen CA
    Mayo Clin Proc; 1970 Sep; 45(9):645-56. PubMed ID: 5311767
    [No Abstract]   [Full Text] [Related]  

  • 17. Biochemical and pharmacological aspects of Parkinsonism.
    Carlsson A
    Acta Neurol Scand Suppl; 1972; 51():11-42. PubMed ID: 4351191
    [No Abstract]   [Full Text] [Related]  

  • 18. [10 years of L-DOPA therapy of Parkinson's syndrome].
    Birkmayer W
    Wien Klin Wochenschr; 1971 Apr; 83(13):221-7. PubMed ID: 4254333
    [No Abstract]   [Full Text] [Related]  

  • 19. Monoamine metabolism and depression in Parkinson patients.
    Puite JK; Schut T; van Praag HM; Lakke JP
    Psychiatr Neurol Neurochir; 1973; 76(1):61-70. PubMed ID: 4699106
    [No Abstract]   [Full Text] [Related]  

  • 20. Accumulation of 3H-homovanillic acid in rabbit brain and cerebrospinal fluid following intravenous 3H-L-dopa.
    Extein I; Roth RH; Bowers MB
    Biol Psychiatry; 1974 Oct; 9(2):161-70. PubMed ID: 4429746
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.